{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:35:27Z","timestamp":1793457327993,"version":"4.5.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002192","name":"LUNGevity Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2020-02"],"award-info":[{"award-number":["2020-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA009666"],"award-info":[{"award-number":["T32 CA009666"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["R01 CA207295"],"award-info":[{"award-number":["R01 CA207295"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["U01 CA213273"],"award-info":[{"award-number":["U01 CA213273"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210159"],"award-info":[{"award-number":["RP210159"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["P50 CA070907"],"award-info":[{"award-number":["P50 CA070907"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["U01 CA256780"],"award-info":[{"award-number":["U01 CA256780"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Cell"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.molcel.2022.12.031","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T11:44:27Z","timestamp":1674128667000},"page":"660-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control"],"prefix":"10.1016","volume":"83","author":[{"given":"Kyle","family":"Concannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin B.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Byers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molcel.2022.12.031_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.molcel.2022.12.031_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2022.12.031_bib3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2022.12.031_bib4","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.molcel.2022.12.031_bib5","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-14-2737","article-title":"MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR Trial","volume":"21","author":"Weller","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib6","doi-asserted-by":"crossref","first-page":"a012583","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib7","doi-asserted-by":"crossref","first-page":"a012609","DOI":"10.1101\/cshperspect.a012609","article-title":"Nucleotide excision repair in eukaryotes","volume":"5","author":"Sch\u00e4rer","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrm1907","article-title":"The multifaceted mismatch-repair system","volume":"7","author":"Jiricny","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib9","doi-asserted-by":"crossref","first-page":"a012575","DOI":"10.1101\/cshperspect.a012575","article-title":"DNA repair by reversal of DNA damage","volume":"5","author":"Yi","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrm.2016.48","article-title":"The Fanconi anaemia pathway: new players and new functions","volume":"17","author":"Ceccaldi","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib11","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1038\/s41467-019-12272-9","article-title":"Molecular basis of microhomology-mediated end-joining by purified full-length Pol\u03b8","volume":"10","author":"Black","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molcel.2022.12.031_bib12","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1093\/nar\/gks270","article-title":"Homologous recombination and its regulation","volume":"40","author":"Krejci","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-biochem-080320-110356","article-title":"Repair of DNA double-strand breaks by the nonhomologous end joining pathway","volume":"90","author":"Stinson","year":"2021","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.molcel.2022.12.031_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","article-title":"Repair pathway choices and consequences at the double-strand break","volume":"26","author":"Ceccaldi","year":"2016","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tig.2014.01.001","article-title":"The role of microhomology in genomic structural variation","volume":"30","author":"Ottaviani","year":"2014","journal-title":"Trends Genet."},{"key":"10.1016\/j.molcel.2022.12.031_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-biochem-062917-012405","article-title":"Translesion and repair DNA polymerases: diverse structure and mechanism","volume":"87","author":"Yang","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.molcel.2022.12.031_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib18","doi-asserted-by":"crossref","first-page":"e101801","DOI":"10.15252\/embj.2019101801","article-title":"DNA damage kinase signaling: checkpoint and repair at 30 years","volume":"38","author":"Lanz","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.molcel.2022.12.031_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.molcel.2022.12.031_bib20","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u201cBRCAness\u201d in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib21","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib22","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/bjc.2012.483","article-title":"The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers","volume":"107","author":"Iqbal","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib23","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib24","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.molcel.2022.12.031_bib25","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.molcel.2022.12.031_bib26","doi-asserted-by":"crossref","first-page":"a016600","DOI":"10.1101\/cshperspect.a016600","article-title":"Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins","volume":"7","author":"Prakash","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.molcel.2022.12.031_bib28","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib29","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib30","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib31","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-cancerbio-030518-055914","article-title":"PARP trapping beyond homologous recombination and platinum sensitivity in cancers","volume":"3","author":"Murai","year":"2019","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib33","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib35","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.molcel.2022.12.031_bib36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib37","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib38","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib39","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib40","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib41","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib42","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib155","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib156","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for\u00a0metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib157","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib158","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 Gene Alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib159","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41467-017-02096-w","article-title":"Target engagement imaging of PARP inhibitors in small-cell lung\u00a0cancer","volume":"9","author":"Carney","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molcel.2022.12.031_bib44","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/bjc.2016.67","article-title":"PARP inhibitors: the race is on","volume":"114","author":"Brown","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib45","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/vaccines9101148","article-title":"Immunological response to COVID-19 vaccination in ovarian cancer patients receiving PARP inhibitors","volume":"9","author":"Liontos","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.molcel.2022.12.031_bib46","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1158\/0008-5472.CAN-14-0839","article-title":"BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance","volume":"75","author":"Jaspers","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib47","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molcel.2022.12.031_bib48","doi-asserted-by":"crossref","first-page":"e02725","DOI":"10.7554\/eLife.02725","article-title":"Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks","volume":"3","author":"Zhao","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.molcel.2022.12.031_bib49","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3892\/ijo.2015.3119","article-title":"Deficient mismatch repair: read all about it (Review)","volume":"47","author":"Richman","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib50","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.celrep.2017.10.032","article-title":"Sensing and processing of DNA interstrand crosslinks by the mismatch repair pathway","volume":"21","author":"Kato","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.molcel.2022.12.031_bib51","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/carcin\/bgs393","article-title":"PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells","volume":"34","author":"Cheng","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.molcel.2022.12.031_bib52","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.molcel.2022.12.031_bib53","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrclinonc.2012.3","article-title":"The potential of exploiting DNA-repair defects for optimizing lung cancer treatment","volume":"9","author":"Postel-Vinay","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib54","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ijc.27822","article-title":"Loss of PBRM1 expression is associated with renal cell carcinoma progression","volume":"132","author":"Paw\u0142owski","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib55","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.molcel.2014.06.028","article-title":"Requirement for PBAF in transcriptional repression and repair at DNA breaks in actively transcribed regions of chromatin","volume":"55","author":"Kakarougkas","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molcel.2022.12.031_bib56","first-page":"637","article-title":"Consequences and resolution of transcription-replication conflicts","volume":"11","author":"Lalonde","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.molcel.2022.12.031_bib57","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1158\/0008-5472.CAN-21-0628","article-title":"PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer","volume":"81","author":"Chabanon","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib58","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ng.907","article-title":"Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder","volume":"43","author":"Gui","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molcel.2022.12.031_bib59","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1101\/gr.137596.112","article-title":"Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer","volume":"22","author":"Liang","year":"2012","journal-title":"Genome Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib60","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2022.12.031_bib61","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/ijgc-2021-002973","article-title":"ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI)","volume":"31","author":"Banerjee","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib62","doi-asserted-by":"crossref","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib63","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer","volume":"80","author":"Rafiei","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib64","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.molcel.2022.12.031_bib65","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/sj.onc.1207528","article-title":"Cell death by mitotic catastrophe: a molecular definition","volume":"23","author":"Castedo","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.molcel.2022.12.031_bib66","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","article-title":"ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency","volume":"74","author":"Mohni","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib67","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.molcel.2015.09.012","article-title":"The fanconi anemia pathway maintains genome stability by coordinating replication and transcription","volume":"60","author":"Schwab","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molcel.2022.12.031_bib68","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-cancerbio-030617-050422","article-title":"The fanconi anemia pathway in cancer","volume":"3","author":"Niraj","year":"2019","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-8-24","article-title":"CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors","volume":"8","author":"Chen","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib70","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res Pharmacol. Drug Discov."},{"key":"10.1016\/j.molcel.2022.12.031_bib71","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in\u00a0patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.molcel.2022.12.031_bib72","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine\u00a0\u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2021.11.011","article-title":"A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer","volume":"163","author":"Plummer","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib74","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib75","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.2015.64.5788","article-title":"Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer","volume":"34","author":"Hong","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib76","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1158\/1078-0432.CCR-17-3347","article-title":"Evaluation of prexasertib, a checkpoint kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma","volume":"24","author":"Hong","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib77","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1111\/cas.13750","article-title":"Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors","volume":"109","author":"Iwasa","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.molcel.2022.12.031_bib78","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2545","article-title":"Immunogenic and tolerogenic cell death","volume":"9","author":"Green","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molcel.2022.12.031_bib79","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molcel.2022.12.031_bib80","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1084\/jem.188.7.1359","article-title":"Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes","volume":"188","author":"Albert","year":"1998","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib81","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","article-title":"Molecular mechanisms and cellular functions of cGAS-STING signalling","volume":"21","author":"Hopfner","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molcel.2022.12.031_bib82","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature23470","article-title":"Mitotic progression following DNA damage enables pattern recognition within micronuclei","volume":"548","author":"Harding","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2022.12.031_bib83","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature23449","article-title":"cGAS surveillance of micronuclei links genome instability to innate immunity","volume":"548","author":"Mackenzie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2022.12.031_bib84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The cytosolic DNA-sensing cGAS-STING pathway in cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2022.12.031_bib85","doi-asserted-by":"crossref","first-page":"11932","DOI":"10.1038\/ncomms11932","article-title":"Activation of STING requires palmitoylation at the Golgi","volume":"7","author":"Mukai","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molcel.2022.12.031_bib86","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41586-019-1000-2","article-title":"Structural basis of STING binding with and phosphorylation by TBK1","volume":"567","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2022.12.031_bib87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","article-title":"DNA damage and cancer immunotherapy: a STING in the tale","volume":"80","author":"Reisl\u00e4nder","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molcel.2022.12.031_bib88","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","article-title":"Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response","volume":"49","author":"Marcus","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.molcel.2022.12.031_bib89","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1158\/0008-5472.CAN-18-1972","article-title":"STING promotes homeostasis via regulation of cell proliferation and chromosomal stability","volume":"79","author":"Ranoa","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1101\/gad.289769.116","article-title":"A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1","volume":"31","author":"Erdal","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.molcel.2022.12.031_bib91","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib92","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.molcel.2022.12.031_bib93","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1074-7613(02)00333-3","article-title":"The role of the NKG2D immunoreceptor in immune cell activation and natural killing","volume":"17","author":"Jamieson","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.molcel.2022.12.031_bib94","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1038\/onc.2008.272","article-title":"NKG2D ligands in tumor immunity","volume":"27","author":"Nausch","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.molcel.2022.12.031_bib95","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1158\/0008-5472.CAN-13-1703","article-title":"RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma","volume":"74","author":"Lam","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib96","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1038\/s41467-019-11048-5","article-title":"BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors","volume":"10","author":"Reisl\u00e4nder","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molcel.2022.12.031_bib97","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molcel.2022.12.031_bib98","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2022.12.031_bib99","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in BRCA1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.molcel.2022.12.031_bib100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib101","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib102","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib103","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","article-title":"The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands","volume":"181","author":"Kinter","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.molcel.2022.12.031_bib104","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T\u00a0cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib105","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.molcel.2022.12.031_bib106","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib107","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib109","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib110","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib111","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.molcel.2022.12.031_bib112","article-title":"Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations)","volume":"5","author":"Mahdi","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib113","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP Inhibitor (Capri): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib114","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1158\/1078-0432.CCR-21-1279","article-title":"Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors","volume":"27","author":"Do","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib115","doi-asserted-by":"crossref","first-page":"111081","DOI":"10.1016\/j.celrep.2022.111081","article-title":"Guiding ATR and PARP inhibitor combinationswith chemogenomic screens","volume":"40","author":"Zimmermann","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.molcel.2022.12.031_bib116","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","article-title":"Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.molcel.2022.12.031_bib117","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2022.12.031_bib118","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jtho.2019.08.009","article-title":"Combination treatment of the oral CHK1 inhibitor, SRA737, and low-dose gemcitabine enhances the effect of programmed death ligand 1 blockade by modulating the immune microenvironment in SCLC","volume":"14","author":"Sen","year":"2019","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib119","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib120","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jtho.2019.04.026","article-title":"Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a Phase\u00a0II study","volume":"14","author":"Thomas","year":"2019","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib121","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molcel.2022.12.031_bib122","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing Phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib123","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib124","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2022.12.031_bib125","doi-asserted-by":"crossref","first-page":"2083755","DOI":"10.1080\/2162402X.2022.2083755","article-title":"PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors","volume":"11","author":"Staniszewska","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.molcel.2022.12.031_bib126","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1038\/onc.2010.11","article-title":"Loss of poly(ADP-ribose) polymerase-2 leads to rapid development of spontaneous T-cell lymphomas in p53-deficient mice","volume":"29","author":"Nicol\u00e1s","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.molcel.2022.12.031_bib127","doi-asserted-by":"crossref","first-page":"41962","DOI":"10.1038\/srep41962","article-title":"PARP-1\/PARP-2 double deficiency in mouse T\u00a0cells results in faulty immune responses and T lymphomas","volume":"7","author":"Navarro","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molcel.2022.12.031_bib128","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib129","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.molcel.2022.12.031_bib130","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-021-00175-8","article-title":"Industrializing engineered autologous T\u00a0cells as medicines for solid tumours","volume":"20","author":"Britten","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molcel.2022.12.031_bib131","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-021-01168-1","article-title":"Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway","volume":"14","author":"Ji","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib132","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","article-title":"Olaparib suppresses MDSC recruitment via SDF1\u03b1\/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice","volume":"29","author":"Sun","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molcel.2022.12.031_bib133","doi-asserted-by":"crossref","first-page":"e20200844","DOI":"10.1084\/jem.20200844","article-title":"STING agonist promotes CAR T\u00a0cell trafficking and persistence in breast cancer","volume":"218","author":"Xu","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib134","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","article-title":"STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molcel.2022.12.031_bib135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41423-018-0086-z","article-title":"Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy","volume":"16","author":"Li","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.molcel.2022.12.031_bib136","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1158\/1078-0432.CCR-20-0458","article-title":"Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: A meta-regression analysis","volume":"26","author":"Osipov","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib137","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib138","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-021-01476-w","article-title":"A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers","volume":"125","author":"Zhang","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib139","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","article-title":"SLFN11 blocks stressed replication forks independently of ATR","volume":"69","author":"Murai","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molcel.2022.12.031_bib140","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/jir.2012.0133","article-title":"The schlafen family of proteins and their regulation by interferons","volume":"33","author":"Mavrommatis","year":"2013","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib141","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-20-4259","article-title":"Veliparib in combination with carboplatin and etoposide in patients with treatment-na\u00efve extensive-stage small cell lung cancer: A Phase 2 randomized study","volume":"27","author":"Byers","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molcel.2022.12.031_bib142","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1186\/s12885-015-1840-6","article-title":"High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment","volume":"15","author":"Deng","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib143","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10549-019-05313-w","article-title":"Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer","volume":"177","author":"Isnaldi","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.molcel.2022.12.031_bib144","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, Phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib145","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41416-020-01199-4","article-title":"SLFN11 informs on standard of care and novel treatments in a wide range of cancer models","volume":"124","author":"Winkler","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib146","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1535-7163.MCT-19-0926","article-title":"SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy","volume":"19","author":"Conteduca","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molcel.2022.12.031_bib147","doi-asserted-by":"crossref","first-page":"eaax2625","DOI":"10.1126\/scitranslmed.aax2625","article-title":"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molcel.2022.12.031_bib148","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/epi-2017-0019","article-title":"Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer","volume":"9","author":"He","year":"2017","journal-title":"Epigenomics"},{"key":"10.1016\/j.molcel.2022.12.031_bib149","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1186\/s12885-020-07574-x","article-title":"The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy","volume":"20","author":"Kagami","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.molcel.2022.12.031_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010004","article-title":"Prognostic significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer","volume":"14","author":"Tserpeli","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molcel.2022.12.031_bib151","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-20-0790","article-title":"DNA polymerase and mismatch repair exert distinct microsatellite instability signatures in normal and malignant human cells","volume":"11","author":"Chung","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2022.12.031_bib152","doi-asserted-by":"crossref","first-page":"e2100267","DOI":"10.1200\/PO.21.00267","article-title":"Clinical and molecular characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.molcel.2022.12.031_bib153","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","article-title":"Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molcel.2022.12.031_bib154","doi-asserted-by":"crossref","first-page":"1777624","DOI":"10.1080\/2162402X.2020.1777624","article-title":"Trial watch: STING agonists in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"}],"container-title":["Molecular Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109727652201214X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109727652201214X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:53:20Z","timestamp":1778590400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109727652201214X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":159,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S109727652201214X"],"URL":"https:\/\/doi.org\/10.1016\/j.molcel.2022.12.031","relation":{},"ISSN":["1097-2765"],"issn-type":[{"value":"1097-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control","name":"articletitle","label":"Article Title"},{"value":"Molecular Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molcel.2022.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}